St Leonards

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• IgA nephropathy2 trials
• Osteoarthritis2 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Chronic kidney disease1 trial
• Chronic myeloid leukaemia1 trial
• Lupus (SLE)1 trial
• Myeloproliferative neoplasms1 trial
• Prostate cancer1 trial
• Thalassaemia1 trial

Phase

• Phase 34 trials
• Phase 23 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting5 trials
• Recruiting2 trials
• Terminated2 trials
• Completed1 trial

Lead sponsor

• Novartis Pharmaceuticals10 trials

Running trials

• Recruiting

  An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

  NCT07206056· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Atrasentan in Patients With Proteinuric Glomerular Diseases

  NCT04573920· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Characterizing the Use of Ofatumumab in a Real World Setting

  NCT05090033· Novartis Pharmaceuticals· Source

• Terminated

  A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

  NCT05462990· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

  NCT04864392· Phase 2· Novartis Pharmaceuticals· Source